The 10th International Symposium on Myelodysplastic Syndromes, held May 6-9 in Patras, Greece, brought MDS doctors and scientists together from around the world to discuss new discoveries and treatment options for myelodysplastic syndromes.
The three-day symposium, sponsored by the MDS Foundation, featured over 40 speakers throughout nine sessions on various topics. Case studies of specific MDS patients, poster sessions, and nursing education programs were also presented.
Several topics of particular interest from the symposium will be featured…
Read the full story »
A new report from Decision Resources finds that the success of drugs Vidaza (azacitidine) and Revlimid (lenalidomide) in the U.S. market has encouraged pharmaceutical companies to devote more resources to drug development for myelodysplastic syndromes (MDS).
Vidaza, which was approved by the FDA in 1994, belongs to a relatively new class of drugs based on epigenetics, which involves changing the production of protein from DNA. In particular, Vidaza helps turn on genes that…
Read the full story »